{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T18:18:18Z","timestamp":1780683498999,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91013-z","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:55:39Z","timestamp":1742493339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development and validation of a scoring system to predict MASLD patients with significant hepatic fibrosis"],"prefix":"10.1038","volume":"15","author":[{"given":"Linjing","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianli","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chutian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"91013_CR1","doi-asserted-by":"crossref","unstructured":"Weiss, J. M. et al. Itaconic Acid underpins hepatocyte lipid metabolism in non-alcoholic fatty liver disease in male mice. Nat. Metab. 5, 981\u2013995 (2023).","DOI":"10.1038\/s42255-023-00801-2"},{"key":"91013_CR2","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1136\/gutjnl-2019-319226","volume":"69","author":"GA Baselli","year":"2020","unstructured":"Baselli, G. A. et al. Liver transcriptomics highlights Interleukin-32 as Novel Nafld-related cytokine and candidate biomarker. Gut 69, 1855\u20131866 (2020).","journal-title":"Gut"},{"key":"91013_CR3","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A Multisociety Delphi Consensus Statement on new fatty liver Disease nomenclature. J. Hepatol. 79, 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"key":"91013_CR4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13293-024-00617-z","volume":"15","author":"L Crudele","year":"2024","unstructured":"Crudele, L. et al. Fatty liver index (Fli) is the best score to Predict Masld with 50% lower cut-off value in women than in men. Biol. Sex. Differ. 15, 43 (2024).","journal-title":"Biol. Sex. Differ."},{"key":"91013_CR5","doi-asserted-by":"crossref","unstructured":"Tao, L. et al. Integrative clinical and preclinical studies identify Ferroterminator1 as a potent therapeutic drug for Mash. Cell. Metab. 36, 2190\u20132206 (2024).","DOI":"10.1016\/j.cmet.2024.07.013"},{"key":"91013_CR6","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/HEP.0000000000000670","volume":"79","author":"F Kanwal","year":"2024","unstructured":"Kanwal, F., Neuschwander-Tetri, B. A., Loomba, R. & Rinella, M. E. Metabolic dysfunction-Associated Steatotic Liver Disease: Update and Impact of New nomenclature on the American Association for the study of Liver diseases Practice Guidance on nonalcoholic fatty liver disease. Hepatology 79, 1212\u20131219 (2024).","journal-title":"Hepatology"},{"key":"91013_CR7","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor, R. S. et al. Association between Fibrosis Stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and Meta-analysis. Gastroenterology 158, 1611\u20131625 (2020).","journal-title":"Gastroenterology"},{"key":"91013_CR8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, Randomized, Controlled Trial of Resmetirom in Nash with Liver Fibrosis. N Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N Engl. J. Med."},{"key":"91013_CR9","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.3748\/wjg.v26.i25.3528","volume":"26","author":"FM Sanai","year":"2020","unstructured":"Sanai, F. M. et al. Management of nonalcoholic fatty liver disease in the Middle East. World J. Gastroenterol. 26, 3528\u20133541 (2020).","journal-title":"World J. Gastroenterol."},{"key":"91013_CR10","doi-asserted-by":"crossref","first-page":"1159055","DOI":"10.3389\/fendo.2023.1159055","volume":"14","author":"Y Shen","year":"2023","unstructured":"Shen, Y., Wu, Y., Fu, M., Zhu, K. & Wang, J. Association between Weight-adjusted-Waist Index with hepatic steatosis and liver fibrosis: a nationally Representative Cross-sectional Study from Nhanes 2017 to 2020. Front. Endocrinol. 14, 1159055 (2023).","journal-title":"Front. Endocrinol."},{"key":"91013_CR11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cmet.2019.10.014","volume":"31","author":"X Sun","year":"2020","unstructured":"Sun, X. et al. Neutralization of oxidized phospholipids ameliorates non-alcoholic Steatohepatitis. Cell. Metab. 31, 189\u2013206 (2020).","journal-title":"Cell. Metab."},{"key":"91013_CR12","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1158\/1078-0432.CCR-18-3669","volume":"26","author":"T Payen","year":"2020","unstructured":"Payen, T. et al. Harmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response. Clin. Cancer Res. 26, 1297\u20131308 (2020).","journal-title":"Clin. Cancer Res."},{"key":"91013_CR13","doi-asserted-by":"crossref","unstructured":"Abenavoli, L. et al. Metabolic dysfunction-Associated Steatotic Liver Disease in patients with inflammatory Bowel diseases: a pilot study. Life-Basel 14, 1226 (2024).","DOI":"10.3390\/life14101226"},{"key":"91013_CR14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/hep.30974","volume":"71","author":"VH Ajmera","year":"2020","unstructured":"Ajmera, V. H. et al. Clinical utility of an increase in magnetic resonance Elastography in Predicting Fibrosis Progression in nonalcoholic fatty liver disease. Hepatology 71, 849\u2013860 (2020).","journal-title":"Hepatology"},{"key":"91013_CR15","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple Noninvasive Index to predict significant fibrosis in patients with Hiv\/Hcv coinfection. Hepatology 43, 1317\u20131325 (2006).","journal-title":"Hepatology"},{"key":"91013_CR16","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo, P. et al. The Nafld Fibrosis score: a noninvasive system that identifies liver fibrosis in patients with Nafld. Hepatology 45, 846\u2013854 (2007).","journal-title":"Hepatology"},{"key":"91013_CR17","doi-asserted-by":"crossref","unstructured":"Vali, Y. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the Litmus Project): a comparative diagnostic accuracy study. Lancet Gastroenterol. Hepatol. 8, 714\u2013725 (2023).","DOI":"10.1016\/S2468-1253(23)00017-1"},{"key":"91013_CR18","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.14309\/ctg.0000000000000165","volume":"11","author":"HK Marella","year":"2020","unstructured":"Marella, H. K. et al. Accuracy of Noninvasive Fibrosis Scoring systems in African American and white patients with nonalcoholic fatty liver disease. Clin. Transl Gastroenterol. 11, e165 (2020).","journal-title":"Clin. Transl Gastroenterol."},{"key":"91013_CR19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","volume":"59","author":"Easl-Easd-Easo","year":"2016","unstructured":"Easl-Easd-Easo. Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59, 1121\u20131140 (2016).","journal-title":"Diabetologia"},{"key":"91013_CR20","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1038\/s41467-020-19589-w","volume":"11","author":"A Molinaro","year":"2020","unstructured":"Molinaro, A. et al. Imidazole propionate is increased in diabetes and Associated with dietary patterns and altered Microbial Ecology. Nat. Commun. 11, 5881 (2020).","journal-title":"Nat. Commun."},{"key":"91013_CR21","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological Scoring System for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"91013_CR22","doi-asserted-by":"crossref","first-page":"106288","DOI":"10.1016\/j.cmpb.2021.106288","volume":"208","author":"F Cabitza","year":"2021","unstructured":"Cabitza, F. et al. The importance of being External. Methodological insights for the External Validation of Machine Learning models in Medicine. Comput. Meth Programs Biomed. 208, 106288 (2021).","journal-title":"Comput. Meth Programs Biomed."},{"key":"91013_CR23","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1038\/s41467-019-13174-6","volume":"10","author":"C Albig","year":"2019","unstructured":"Albig, C. et al. Jasper Controls Interphase histone H3S10 phosphorylation by chromosomal kinase Jil-1 in Drosophila. Nat. Commun. 10, 5343 (2019).","journal-title":"Nat. Commun."},{"key":"91013_CR24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12859-017-1547-6","volume":"18","author":"JS Shah","year":"2017","unstructured":"Shah, J. S. et al. Distribution based nearest neighbor imputation for truncated high Dimensional data with applications to pre-clinical and clinical Metabolomics studies. BMC Bioinform. 18, 114 (2017).","journal-title":"BMC Bioinform."},{"key":"91013_CR25","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"FE Harrell","year":"2001","unstructured":"Harrell, F. E. Regression Modeling Strategies: with Applications to Linear Models, Logistic Regression, and Survival AnalysisVol. 608 (Springer, 2001)."},{"key":"91013_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v007.i02","volume":"7","author":"A Zeileis","year":"2002","unstructured":"Zeileis, A., Leisch, F., Hornik, K., Kleiber, C. & Strucchange An R Package for Testing for Structural Change in Linear Regression models. J. Stat. Softw. 7, 1\u201338 (2002).","journal-title":"J. Stat. Softw."},{"key":"91013_CR27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1158\/1078-0432.CCR-16-0594","volume":"23","author":"L Yu","year":"2017","unstructured":"Yu, L. et al. Survival of Del17P cll depends on genomic complexity and somatic mutation. Clin. Cancer Res. 23, 735\u2013745 (2017).","journal-title":"Clin. Cancer Res."},{"key":"91013_CR28","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","volume":"57","author":"SA Harrison","year":"2008","unstructured":"Harrison, S. A., Oliver, D., Arnold, H. L., Gogia, S. & Neuschwander-Tetri, B. A. Development and validation of a simple Nafld Clinical Scoring System for identifying patients without Advanced Disease. Gut 57, 1441\u20131447 (2008).","journal-title":"Gut"},{"key":"91013_CR29","doi-asserted-by":"crossref","first-page":"e28858","DOI":"10.1002\/jmv.28858","volume":"95","author":"Z Wu","year":"2023","unstructured":"Wu, Z., Wang, W., Zhang, K., Fan, M. & Lin, R. Trends in the incidence of cirrhosis in global from 1990 to 2019: a joinpoint and age-period-cohort analysis. J. Med. Virol. 95, e28858 (2023).","journal-title":"J. Med. Virol."},{"key":"91013_CR30","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/hep.30094","volume":"68","author":"AM Allen","year":"2018","unstructured":"Allen, A. M., Van Houten, H. K., Sangaralingham, L. R., Talwalkar, J. A. & McCoy, R. G. Healthcare Cost and utilization in nonalcoholic fatty liver disease: real-World Data from a large U.S. Claims Database. Hepatology 68, 2230\u20132238 (2018).","journal-title":"Hepatology"},{"key":"91013_CR31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/hep.32545","volume":"77","author":"P Sripongpun","year":"2023","unstructured":"Sripongpun, P. et al. The steatosis-Associated Fibrosis Estimator (Safe) score: a Tool to detect low-risk Nafld in Primary Care. Hepatology 77, 256\u2013267 (2023).","journal-title":"Hepatology"},{"key":"91013_CR32","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","volume":"68","author":"T Jensen","year":"2018","unstructured":"Jensen, T. et al. Fructose and Sugar: a major mediator of non-alcoholic fatty liver disease. J. Hepatol. 68, 1063\u20131075 (2018).","journal-title":"J. Hepatol."},{"key":"91013_CR33","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.3748\/wjg.v25.i33.4959","volume":"25","author":"JI Lee","year":"2019","unstructured":"Lee, J. I., Lee, H. W. & Lee, K. S. Value of controlled attenuation parameter in Fibrosis Prediction in Nonalcoholic Steatohepatitis. World J. Gastroenterol. 25, 4959\u20134969 (2019).","journal-title":"World J. Gastroenterol."},{"key":"91013_CR34","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/hep.26465","volume":"58","author":"M Noureddin","year":"2013","unstructured":"Noureddin, M. et al. Clinical and histological determinants of nonalcoholic steatohepatitis and Advanced Fibrosis in Elderly patients. Hepatology 58, 1644\u20131654 (2013).","journal-title":"Hepatology"},{"key":"91013_CR35","first-page":"823","volume":"66","author":"TG Andrade","year":"2022","unstructured":"Andrade, T. G., Xavier, L., Souza, F. F. & Araujo, R. C. Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver Disease - A Survey in a University Hospital in Brazil. Arch. Endocrinol. Metab. 66, 823\u2013830 (2022).","journal-title":"Arch. Endocrinol. Metab."},{"key":"91013_CR36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hep.29113","volume":"66","author":"A Unalp-Arida","year":"2017","unstructured":"Unalp-Arida, A. & Ruhl, C. E. Liver Fibrosis scores Predict Liver Disease Mortality in the United States Population. Hepatology 66, 84\u201395 (2017).","journal-title":"Hepatology"},{"key":"91013_CR37","first-page":"518","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai, C. T. et al. A simple Noninvasive Index can predict both significant fibrosis and cirrhosis in patients with chronic Hepatitis C. Hepatology 38, 518\u2013526 (2003).","journal-title":"Hepatology"},{"key":"91013_CR38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/jvh.13808","volume":"30","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. A novel non-invasive model for the prediction of Advanced Liver Fibrosis in Chronic Hepatitis B patients with Nafld. J. Viral Hepat. 30, 287\u2013296 (2023).","journal-title":"J. Viral Hepat."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91013-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91013-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91013-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:56:46Z","timestamp":1742493406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91013-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91013"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91013-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the ethics committee of Jinan university first affiliated hospital (Approval number: KY-2022-231).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients signed a written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent Statement"}}],"article-number":"9639"}}